908 Devices Inc. (NASDAQ:MASS - Get Free Report) CEO Kevin J. Knopp purchased 10,000 shares of the firm's stock in a transaction that occurred on Tuesday, May 7th. The stock was bought at an average cost of $5.60 per share, for a total transaction of $56,000.00. Following the completion of the purchase, the chief executive officer now directly owns 468,981 shares in the company, valued at approximately $2,626,293.60. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website.
908 Devices Price Performance
Shares of 908 Devices stock opened at $5.70 on Wednesday. The business has a 50 day simple moving average of $6.48 and a two-hundred day simple moving average of $7.08. The stock has a market capitalization of $187.99 million, a P/E ratio of -5.33 and a beta of 1.02. 908 Devices Inc. has a 12 month low of $4.85 and a 12 month high of $12.51.
908 Devices (NASDAQ:MASS - Get Free Report) last posted its quarterly earnings data on Tuesday, April 30th. The company reported ($0.33) EPS for the quarter, beating the consensus estimate of ($0.36) by $0.03. 908 Devices had a negative return on equity of 20.47% and a negative net margin of 68.57%. The firm had revenue of $9.99 million during the quarter, compared to the consensus estimate of $9.29 million. During the same period in the prior year, the company earned ($0.39) EPS. The firm's revenue was up 5.3% compared to the same quarter last year. As a group, research analysts anticipate that 908 Devices Inc. will post -1.11 EPS for the current fiscal year.
Hedge Funds Weigh In On 908 Devices
The ONE AI Stock to own now. (It’s not Nvidia.)
From Weiss Ratings | Ad
Don’t panic — you haven’t missed the boat on AI.
In fact, it has barely launched.
Sure, the early stages of this boom were big …
But I believe the real wealth in AI has yet to be made …
Click here to see the presentation now.
A number of institutional investors and hedge funds have recently bought and sold shares of MASS. AWM Investment Company Inc. acquired a new stake in 908 Devices in the 3rd quarter valued at about $3,740,000. ARK Investment Management LLC increased its holdings in shares of 908 Devices by 8.3% in the fourth quarter. ARK Investment Management LLC now owns 4,346,579 shares of the company's stock valued at $48,769,000 after purchasing an additional 333,119 shares during the last quarter. Iron Triangle Partners LP increased its holdings in shares of 908 Devices by 31.1% in the fourth quarter. Iron Triangle Partners LP now owns 1,284,947 shares of the company's stock valued at $14,417,000 after purchasing an additional 304,484 shares during the last quarter. Granahan Investment Management LLC lifted its position in 908 Devices by 10.6% during the fourth quarter. Granahan Investment Management LLC now owns 2,038,658 shares of the company's stock worth $22,874,000 after buying an additional 195,368 shares in the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. boosted its stake in 908 Devices by 3.0% during the third quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 629,994 shares of the company's stock worth $4,196,000 after buying an additional 18,492 shares during the last quarter. 88.06% of the stock is currently owned by institutional investors and hedge funds.
908 Devices Company Profile
(
Get Free Report)
908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
